A companion piece to this one looked at what medical care actually costs in Malaysia right now — hospital and insurer costs rising 15 to 16% a year, private clinic fees frozen since 1992. This piece is about a related but separate question: not whether Malaysian insurers price by health status — they do, and the private market’s freedom to do so is well established — but whether Malaysia has decided what it wants its new government-backed base plan to actually be.

MediAsas, launched into pilot in July 2026, sits at the intersection of two different policy instruments. As a voluntary, fully underwritten insurance product it is coherent on its own terms. As a social protection mechanism for people the private market currently fails, it has a significant gap at its centre: it can exclude the very conditions most likely to make someone uninsurable in the first place. That gap is not accidental. It is a design choice — one Malaysia has not yet made explicitly — and the people best placed to close it have already said so, in public, by name.

Private insurers in Malaysia routinely exclude pre-existing conditions outright, or cover them only after waiting periods that commonly run from six months to five years depending on the condition and the insurer. Premiums are explicitly risk-rated by age and health status — the older or sicker you are, the more you pay for the same cover, where you can get it at all.

The scale of the problem is measurable. The January 2026 white paper on the Base MHIT Plan, co-authored by MOF, MOH and BNM, records that an estimated 340,000 MHIT policies — 5.2% of all policies — were surrendered between January 2024 and June 2025, net of reinstatements. Those are people who had private medical cover and no longer do. Most of them will now depend on public hospitals if they need serious care.

What the government’s new plan actually does

This is not only a feature of the private commercial market. It is now built into the design of the government’s own new base medical insurance product, which has since acquired a name and entered a live pilot. Bank Negara Malaysia’s 22-page FAQ on the pilot version, dated 29 July 2026, describes MediAsas as a key component of the Reset strategy jointly run by MOH, the Ministry of Finance and BNM to address medical inflation. It comes in two products — MediAsas Teras, capped at RM100,000 a year under 60 and RM150,000 above it; and MediAsas Fleksi, offering RM300,000 a year with a RM10,000 to RM15,000 deductible — with monthly premiums of roughly RM60 to RM550. Neither product imposes a lifetime limit, which is a genuine structural distinction from most private plans currently on the market. BNM’s own claims data show that 99% of claims paid in 2024 were below RM60,000, suggesting the annual limits are adequate for most ordinary hospital episodes; they may prove insufficient for repeated admissions, prolonged treatment or expensive cancer therapies.

On the specific question this piece is about, BNM’s own pilot FAQ, published 29 July 2026, is more detailed — and more restrictive — than earlier public messaging suggested. Ministerial statements as recently as February 2026 described MediAsas as covering “controlled pre-existing conditions,” which is not quite what the pilot terms say. MediAsas is fully underwritten: applicants must disclose their health history, and a condition that already existed can be excluded outright at the point of application. The seven-year “no look-back” provision does something narrower than the earlier framing implied — after seven continuous years, a claim generally cannot be contested on the grounds of non-disclosure alone. It does not retroactively cover a condition that was excluded in writing from day one.

Even the non-disclosure protection has its own limits. It does not apply to non-disclosure found to be “fraudulent, deliberate, or reckless,” and separately does not apply to a defined list of “Pre-Defined Medical Conditions” that existed before the policy began — a list that runs wider than the cancer and cardiovascular examples usually cited, extending to end-stage organ failure and transplants, major neurological disorders, and certain systemic autoimmune conditions. For someone already living with one of these conditions, the exclusion is not seven years. It is the length of the policy.

The response from people who study health financing for a living has been blunt. Prof Emeritus Dr Syed Mohamed Aljunid Syed Junid, a health economics professor at IMU University, called for MediAsas to be cancelled outright, saying it was essentially no different from existing private insurance despite being marketed as reform. Tanjong Karang MP Dr Zulkafperi Hanapi made the same call in Parliament, arguing the pre-existing condition exclusion leaves the sick and elderly unprotected while the annual limit is too uncompetitive to attract the young and healthy either — satisfying neither side of the risk pool it depends on.

Not every considered voice agrees the scheme should be scrapped. Dr Khor Swee Kheng, a health systems specialist and CEO of Angsana Health, writing in The Edge Malaysia, broadly welcomed MediAsas, describing it as good policy and necessary, while framing it as a “foundation stone” for further reform rather than a finished answer. He points to real, distinguishing features: MediAsas is not sold bundled into an investment product, unlike more than 70% of existing medical plans on the market. Those bundled products typically carry insurance charges that rise substantially as policyholders age, raising a real question about whether they remain affordable at retirement — precisely when coverage matters most. MediAsas is designed to run to age 85, well past where most private plans currently cut cover off.

Two further pieces of evidence temper optimism either way. CodeBlue has separately identified at least five existing private plans offering annual limits of RM1 million to RM5 million at premiums comparable to or below MediAsas Teras — for a young, healthy applicant able to pass underwriting, MediAsas is not obviously the best available option, only the most standardised one. And economist Geoffrey Williams, a professor at ELM Graduate School, HELP University, has warned of a crowding-out risk: if healthier applicants migrate to the cheaper standardised plan, the risk pool left behind at existing insurers skews sicker, which can push those insurers’ premiums up rather than down.

A separate, older government scheme is worth knowing about as a caution on execution rather than design. mySalam, the free B40 critical-illness takaful scheme, paid out only about 54% of critical illness and hospitalisation claims between 2019 and 2024, according to a CodeBlue analysis of the scheme’s own data. Good policy design on paper is not the same as a scheme that reliably pays out in practice, and MediAsas’s eventual record on that measure will matter as much as anything written into its terms today.

The scheme itself is confirmed and dated, not speculative. The Ministry of Finance’s own press release on 6 July 2026 names MediAsas as the brand for the Base MHIT Plan, endorsed by a Joint Ministerial Committee co-chaired by the Finance Minister II and the Health Minister. Its pilot runs in the Klang Valley, end July to October 2026, with six named insurers and takaful operators and ten hospitals. Bank Negara’s own page on the pilot is specific about who is actually affected during this phase: participants are staff of selected statutory bodies, GLCs and SMEs, and “most Malaysians will not be affected during this phase.” Coverage under the full scheme is intended to run to age 85, with a basic monthly premium the Health Minister has put at around RM65, though he was careful to say the conditions, pricing, and inclusion and exclusion criteria were all still being finalised as of that statement.

I want to be fair to the designers of this plan, and BNM’s own page for the scheme is itself fairly direct about what MediAsas is not: it states plainly that MediAsas “is not a social insurance/takaful scheme” — which is a clearer answer to one of this piece’s own questions than anything an outside critic has offered. A voluntary product that is explicitly actuarially bounded, not redistributive, is a coherent design choice — provided it is communicated as that rather than as a social protection mechanism for people the private market currently fails to serve — which is how ministerial statements have frequently described it. If government intends MediAsas to function as a genuine social protection mechanism, its underwriting rules leave a significant protection gap. If it is intended as a standardised voluntary insurance product, its public positioning needs to be considerably clearer.

One further detail is worth including for balance. There is already a body meant to handle exactly the kind of clinical dispute this piece has described. The Healthcare Partners Protocol and Solutions Committee, previously called the Grievance Mechanism Committee, brings together MMA, APHM, the Life Insurance Association of Malaysia, the general and takaful insurance associations, with MOH and BNM as observers, specifically to review guarantee-letter disputes and hospital-charge disagreements. Its existence raises a practical question: how widely known, accessible and used is the mechanism in practice? Either way, better visibility for a mechanism that, on paper, already does much of what specialists asked for is the obvious first step.

The timeline is still worth noting on its own terms: public launch is slated for January 2027, with the next general election due by February 2028. Whether the seven-year moratorium works as intended will not be knowable until roughly 2034 — well past both dates, and well past the tenure of whoever designed it.

What the comparison countries do differently

None of what follows is a claim that Malaysia must copy any of these systems wholesale. Each was built for a different fiscal base, a different population, a different political settlement. But the structural choice each has made is worth setting out plainly, because it shows the Malaysian arrangement is not the only way a country in this region has solved the problem.

Singapore. MediShield Life, the compulsory national scheme administered through the Central Provident Fund, covers every citizen and permanent resident for life, including those with pre-existing conditions, with no exclusions. Those with the most serious pre-existing conditions paid a 30% additional premium for a transition period — which ended in 2025. As of now, a Singaporean newly diagnosed with a serious chronic illness pays the same MediShield Life premium as anyone else their age. The qualification worth noting is that Integrated Shield Plans — private top-up products that sit above MediShield Life — retain their own underwriting and can still exclude or load for pre-existing conditions. The no-exclusion guarantee applies to the compulsory base layer, not the full private market.

Australia. The more important feature of the Australian system is not its community rating rule but its architecture. Medicare, the tax-funded universal scheme, covers every resident regardless of health status, income or insurance status. Private health insurance sits on top of Medicare as a supplementary layer — it funds shorter waiting times, private hospital rooms and choice of specialist, but it is not the difference between treatment and no treatment. The community rating requirement means private insurers cannot set premiums by health status; pre-existing condition exclusions are permitted for a maximum of 12 months, after which the condition must be covered at standard rates. In Australia, private insurance largely affects timing, provider choice and treatment setting; the underlying entitlement to medically necessary care remains with Medicare. In Malaysia, private coverage can have a much greater bearing on whether timely private treatment is financially accessible at all. The public floor exists, but its capacity is under significant and worsening pressure: MOH’s doctor workforce contracted in 2024 for the first time in a decade, losing 1,444 doctors while the private sector gained nearly 4,700 in the same year. MOH’s own projections show the public sector is currently short of nearly 11,000 specialists.

United States. Since the Affordable Care Act, insurers in ACA-regulated individual and small-group markets are prohibited by federal law from denying coverage, charging more, or excluding benefits because of a pre-existing condition. Employer self-insured plans, Medicare, Medicaid and grandfathered arrangements operate under different rules, but for the market most comparable to Malaysia’s private insurance sector the prohibition is absolute. This is enforced through two linked mechanisms: guaranteed issue, meaning an insurer must offer a policy to any eligible applicant regardless of health status, and community rating, meaning the premium charged cannot vary by health status at all — only by age (capped at a 3:1 ratio), geography, tobacco use and family size.

Thailand. The Universal Coverage Scheme, launched in 2002 and still commonly called the 30-Baht Scheme after its original copayment, is tax-funded and covers 98% of the population as a matter of citizenship rather than underwritten insurance. Pre-existing conditions are not a question that arises, because eligibility was never assessed on health status in the first place. Civil servants and formal-sector employees are covered by separate schemes, but the UCS alone accounts for roughly 71% of the population.

Four different mechanisms — a compulsory national scheme with a since-expired transition surcharge, a universal public floor with community-rated private insurance above it, a federal prohibition on health-status pricing in regulated markets, and tax-funded universal citizenship — arrive at the same destination. In each, a serious diagnosis does not permanently determine access to the core layer of health protection. In Malaysia’s private market, and in MediAsas, the base plan our own central bank has designed to sit beneath it, being newly diagnosed changes what you pay for as long as you keep paying, or excludes the condition permanently.

The comparison is instructive, but it requires one qualification to be economically honest. Insurance works because many contributors subsidise relatively few large claims. If a system prohibits health-status underwriting — refusing to price or exclude by pre-existing condition — it must replace the risk-management function that underwriting performs with something else. The options are compulsory participation, so that healthy people cannot opt out and leave only the sick in the pool; community rating, so that premiums are shared rather than individualised; government subsidies, to make premiums affordable for those who would otherwise be priced out; risk equalisation between insurers, so that no single company is penalised for attracting sicker members; or government reinsurance for the highest-cost cases. Each of the four comparison countries uses some combination of these. Malaysia’s current framework uses none of them in the private market, which is why adverse selection is a genuine constraint rather than a theoretical one — and why the crowding-out concern already noted in this piece is not simply an argument against MediAsas but a description of what happens to any voluntary pool when the healthy leave it. BNM’s own White Paper on the Base MHIT Plan acknowledges this directly, noting that full community rating under a voluntary system “increases adverse selection where healthier lives delay or refrain from buying insurance/takaful until they are sick, causing the overall experience of the pool to deteriorate and eventually become unaffordable and unsustainable.” The constraint is not an outside critic’s objection. It is BNM’s own stated rationale for risk-rating the Base MHIT Plan premiums.

None of this is to say Malaysia must replicate any one of these models wholesale. Malaysia’s two-tier public/private architecture, combined with the absence of a compulsory national scheme, makes direct import of any single model difficult — but the regional picture makes clear that the choice Malaysia has made in MediAsas is not the only available one, and that other countries with very different fiscal and institutional constraints have made a different choice.

The following table sets out where each country in this region stands on this question.

Asia-Pacific: pre-existing conditions and national health insurance coverage

★ = primary official source verified directly. ⚠ = secondary or academic source; verify against national authority before citing. “Coverage” refers to the national or compulsory public scheme only — the private market in every country listed applies some form of underwriting or exclusion unless explicitly regulated otherwise. Brunei is omitted: its fully government-funded system covers all citizens by right with no insurance mechanism, making the PEC question moot. Timor-Leste omitted for insufficient primary data.

What insurers actually do, in specialists’ own words

Three separate questions run through any insurance dispute, and keeping them distinct matters. The first is clinical: is the treatment medically necessary? The second is professional: is it appropriate according to accepted practice? The third is contractual: is it covered under this policy? An insurer can legitimately answer no to the third question even when the answer to the first two is yes — that is what policy exclusions and waiting periods exist to do. The concern raised by the specialists surveyed here is not with that legitimate function. It is with decisions in which a contractual coverage determination is presented as though it were a clinical judgement, or in which an administrator’s reading of a policy substitutes for a clinician’s assessment of a patient. Those are different things, and the survey’s findings are most precisely read as evidence of the second problem, not the first.

Structure and pricing are one part of the story. There is a separate, more direct question: when a claim is actually made, what does an insurer do with it? A nationwide survey answers that with more specificity than a general complaint usually offers.

In October 2025, CodeBlue surveyed 855 specialists practising in private hospitals across Malaysia about their experience of health insurers and third-party administrators. The pattern that emerged was consistent enough that CodeBlue titled it “Deny, Delay, Revoke,” and the specific examples specialists gave hold up against the label.

The reported pattern of denials clustered around a small number of recurring tactics: respondents described reclassification of a condition to move it outside a policy’s covered categories, invocation of a pre-existing condition clause against a finding that was incidental to the illness being treated, and treatment of routine markers of metabolic disease — diabetes, being overweight, elevated cholesterol — as disqualifying even where they had no bearing on the presenting emergency. One specialist described a jaw tumour requiring reconstruction being rejected on the grounds it counted as “dental treatment.” Another described a patient’s guarantee letter for surgery being revoked after discharge because diabetes, discovered incidentally during an unrelated admission, was deemed undisclosed.

Delays followed a similar pattern: respondents described insurers requesting repeated documentation for procedures with no realistic alternative timeline, with several respondents reporting that emergency surgery was pushed past midnight while a guarantee letter was pending. And revocations — approval withdrawn after treatment had already been given, as respondents described it — were experienced by 67% of respondents, who cited the insurer’s grounds as a finding that a normal test result after treatment proved the treatment had not been necessary in the first place — reasoning that, if accurately reported, inverts the purpose of early intervention.

An endocrinologist quoted in the survey put the underlying complaint precisely: insurers, he said, “do not and should not have the right to dictate medical treatment.” Several specialists independently proposed the same fix — an independent medical review board or ombudsman with the clinical standing to adjudicate disputes, rather than leaving the question to administrative staff applying contract language to clinical decisions.

That avenue exists, formally, since 1 January 2025. The Financial Markets Ombudsman Service was created by merging two predecessor bodies, is appointed jointly by Bank Negara and the Securities Commission, and offers free, independent adjudication of exactly this kind of dispute. Whether patients and specialists know to use it — rather than paying quietly to avoid a drawn-out fight, which is what CodeBlue’s respondents said most often actually happens — is a separate and, I think, more urgent question than whether the mechanism exists on paper. A practical guide to disputing a claim, including how to use FMOS, is at What to Do If Your Claim Is Denied.

So what would actually help

1. Say the same thing everywhere the public reads about MediAsas. BNM’s own page states clearly that MediAsas is not a social insurance scheme. Ministerial statements and press coverage lean the other way, describing it as expanding protection to the uninsured. Both can be true at once, but a 70-year-old diabetic deciding whether to apply needs the plainer of the two framings stated up front, not found by reading the regulator’s fine print after a ministerial press release has already set expectations.
2. Look directly at what ended the Singapore surcharge. MediShield Life’s ten-year additional-premium period for serious pre-existing conditions was a deliberate, dated transition mechanism, not an indefinite feature. If MediAsas keeps any risk-rated or exclusionary element, a similarly dated sunset — rather than a permanent carve-out for Pre-Defined Medical Conditions — is a specific, costed policy question worth asking before January 2027, not after.
3. Publicise FMOS, deliberately. A free, independent dispute body has existed since January 2025 and specialists’ own testimony suggests most patients still do not use it, quietly paying disputed bills instead. That is a solvable awareness gap, not a structural one, and cheaper to fix than anything else in this list.
4. Require clinical review where decisions turn on clinical judgement. Several specialists proposed this themselves: any guarantee letter decision that turns on clinical judgement, not contract wording, should carry the name and qualification of the medical professional who made it, not an administrator’s alone. It would not stop insurers managing cost. It would make transparent whether a decision rests on medical judgement, contractual interpretation or cost management.

5. Invest in chronic disease management as an insurance argument, not only a public health one. Better management of chronic disease in the community — through whatever combination of monitoring, telehealth and primary care investment Malaysia builds next — reduces the frequency and severity of the acute episodes that drive the largest insurance claims. The insurance argument is distinct from the public health one: a risk pool whose members are better managed is a cheaper risk pool to sustain, and cheaper pools charge lower premiums. That is an argument for investing in chronic disease infrastructure that connects directly to the insurance affordability problem this article is about, and it is made at greater length in a companion piece on Malaysia’s still-uncommenced Telemedicine Act.

In short

Malaysia sits in an unusual position by regional standards: Singapore, Australia, the United States and Thailand have each, by a different mechanism, taken the question of whether you are already sick off the table when deciding what you pay or whether you are covered at all. Malaysia’s new government-backed base medical insurance product, launched into pilot this year under the name MediAsas, has not made that choice — and the people who study this for a living have said so publicly, by name, before the scheme has even reached its public launch. Separately, a nationwide survey of specialists shows that even where coverage exists on paper, specialists surveyed reported recurring instances of denial, delay and revocation in practice, citing reasons that had more to do with contract administration than clinical judgement.

Both problems have the same shape. A promise made at the point of sale — protection, if you need it — is not the same as protection delivered at the point of need. Closing that gap is a policy choice, not a law of economics, and several of the people best placed to close it have already said, in public, exactly what they think should change.

Malaysia’s insurance framework has left a persistent protection gap for people who become sick, and the current reform process is an opportunity to close it without further delay. A scheme that does not price out the sick, a regulator willing to enforce the conduct rules that already exist, and a dispute body that patients actually know to use — none of these require waiting for January 2027. The machinery is now being built. The question is whether Malaysia will decide that protection means being insured when healthy — or being protected when sick.